Please fill out our easy to use form below. We will contact you today. Or, call us 24/7 TOLL FREE at 877-934-6274.
  • MM slash DD slash YYYY
  • By submitting this form you acknowledge that you have read the Terms of Use and accept the terms of this agreement.

June 15, 2020: FDA Warns of Potential Drug Interaction Between Remdesivir and Hydroxychloroquine

Remdesivir Drug Interaction News – The U.S. Food and Drug Administration (FDA) has warned of a newly discovered potential drug interaction between remdesivir and chloroquine phosphate or hydroxychloroquine sulfate, which can reduce the effectiveness of remdesivir.

Remdesivir Drug Interaction Information

On June 15, 2020, the FDA announced that the co-administration of remdesivir and chloroquine phosphate or hydroxychloroquine sulfate is not recommended as when remdesivir is mixed with the latter two drugs, a reduction in the effectiveness of remdesivir’s treatment may occur.

Per Patrizia Cavazzoni, M.D., acting director of the FDA’s Center for Drug Evaluation and Research:

Over the course of this unprecedented pandemic, the FDA has issued emergency use authorizations for a variety of medical products after evaluating the available scientific evidence and carefully balancing any known or potential risks against the benefits of making these products available during the current public health emergency. We understand that, as we learn more about these products, changes may be necessary based on new data – such as today’s updates for health care providers about a potential drug interaction and other important information about using remdesivir to treat COVID-19 patients. As we have done throughout the pandemic, the FDA continues to evaluate all of the emergency use authorizations issued and their related materials and will continue to make changes as appropriate based on emerging science and data.

The FDA issued an Emergency Use Authorization (EUA) in early May 2020 for the use of remdesivir to treat suspected or laboratory-confirmed COVID-19 cases in adults and pediatric patients hospitalized with severe disease. Remdesivir’s safety and efficacy for the treatment of COVID-19 continues to be evaluated, but preliminary clinical trial results show, on average, that patients treated with remdesivir have had a quicker recovery time.

About The Weinberg Law Firm

Since 1984, The Weinberg Law Firm has represented individuals in personal injury and wrongful death claims, focusing primarily on food and pharmaceutical drug law, defective products, class action litigation, accidents, and medical malpractice.

To learn about our additional legal services please see Food Poisoning LawyerPharmaceutical Drug Litigation, and Consumer Product Lawsuit.

If you have a case-specific question, or a question regarding our legal services, please select
Contact Weinberg Law Firm. You may also call us 24/7 at our toll free number, 1(877) 934-6274.